Cargando…

Predicting the Development of Renal Replacement Therapy Indications by Combining the Furosemide Stress Test and Chemokine (C-C Motif) Ligand 14 in a Cohort of Postsurgical Patients

Optimal timing of renal replacement therapy (RRT) initiation in severe acute kidney injury (AKI) remains controversial. Initiation of treatment early in the course of AKI may lead to some patients undergoing unnecessary RRT, whereas delayed treatment is associated with increased mortality. This stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meersch, Melanie, Weiss, Raphael, Gerss, Joachim, Albert, Felix, Gruber, Janik, Kellum, John A., Chawla, Lakhmir, Forni, Lui G., Koyner, Jay L., von Groote, Thilo, Zarbock, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335738/ https://www.ncbi.nlm.nih.gov/pubmed/36988335 http://dx.doi.org/10.1097/CCM.0000000000005849

Ejemplares similares

Serial Urinary C-C Motif Chemokine Ligand 14 and Risk of Persistent Severe Acute Kidney Injury
por: Prowle, John R., et al.
Publicado: (2023)

The AKI care bundle: all bundle components are created equal—are they?
por: von Groote, Thilo C., et al.
Publicado: (2021)

Use of Cell Cycle Arrest Biomarkers in Conjunction With Classical Markers of Acute Kidney Injury
por: Joannidis, Michael, et al.
Publicado: (2019)

External validation of urinary C–C motif chemokine ligand 14 (CCL14) for prediction of persistent acute kidney injury
por: Bagshaw, Sean M., et al.
Publicado: (2021)

Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and Pharmacokinetics
por: Weiss, Raphael, et al.
Publicado: (2023)

Evaluation of Proenkephalin A 119–159 for liberation from renal replacement therapy: an external, multicenter pilot study in critically ill patients with acute kidney injury
por: von Groote, Thilo, et al.
Publicado: (2023)

The furosemide stress test: current use and future potential
por: McMahon, Blaithin A., et al.
Publicado: (2021)

Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial
por: Zarbock, Alexander, et al.
Publicado: (2016)

Erratum to: ‘Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial’
por: Zarbock, Alexander, et al.
Publicado: (2016)

Development and Standardization of a Furosemide Stress Test to Predict the Severity of Acute Kidney Injury
por: Chawla, Lakhmir S, et al.
Publicado: (2013)

Proenkephalin A 119–159 predicts early and successful liberation from renal replacement therapy in critically ill patients with acute kidney injury: a post hoc analysis of the ELAIN trial
por: von Groote, Thilo, et al.
Publicado: (2022)

Broad spectrum vasopressors: a new approach to the initial management of septic shock?
por: Chawla, Lakhmir S., et al.
Publicado: (2019)

Cytotoxic chemotherapy reduces T cell trafficking to the spleen by downregulating the expression of C-C motif chemokine ligand 21 and C-C motif chemokine ligand 19
por: Liu, Lina, et al.
Publicado: (2018)

Furosemide stress test and interstitial fibrosis in kidney biopsies in chronic kidney disease
por: Rivero, Jesús, et al.
Publicado: (2020)

Why the renin–angiotensin–aldosterone system (RAAS) in critically ill patients can no longer be ignored
por: Zarbock, Alexander, et al.
Publicado: (2021)

Cell-cycle arrest and acute kidney injury: the light and the dark sides
por: Kellum, John A., et al.
Publicado: (2016)

Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial
por: Meersch, Melanie, et al.
Publicado: (2017)

Potentials of C‐C motif chemokine 2–C‐C chemokine receptor type 2 blockers including propagermanium as anticancer agents
por: Yumimoto, Kanae, et al.
Publicado: (2019)

Chemokine (C-X-C motif) ligand 1/chemokine (C-X-C motif) receptor 2 autocrine loop contributes to cellular proliferation, migration and apoptosis in cervical cancer
por: Sun, Jiping, et al.
Publicado: (2022)

Common chronic conditions do not affect performance of cell cycle arrest biomarkers for risk stratification of acute kidney injury
por: Heung, Michael, et al.
Publicado: (2016)

Plasma levels of monokine induced by interferon-gamma/chemokine (C-X-X motif) ligand 9, thymus and activation-regulated chemokine/chemokine (C-C motif) ligand 17 in children with Kawasaki disease
por: Feng, Siqi, et al.
Publicado: (2015)

The Significance of Selected C-C Motif Chemokine Ligands in Colorectal Cancer Patients
por: Zajkowska, Monika, et al.
Publicado: (2022)

Biomarkers for the Prediction and Judgement of Sepsis and Sepsis Complications: A Step towards precision medicine?
por: von Groote, Thilo, et al.
Publicado: (2022)

Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with FTY720 prolongs the survival of cardiac retransplantation allografts in a mouse model
por: MA, TENG, et al.
Publicado: (2015)

Permissive hypofiltration
por: Chawla, Lakhmir S, et al.
Publicado: (2012)

Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain
por: Selenica, Maj-Linda B, et al.
Publicado: (2013)

Role of chemokine C-C motif ligand-1 in acute and chronic pulmonary inflammations
por: Kishi, Hiroyuki, et al.
Publicado: (2016)

Expression of C–C motif chemokines and their receptors in bovine placentomes at spontaneous and induced parturition
por: HIRAYAMA, Hiroki, et al.
Publicado: (2019)

Vascular Stem/Progenitor Cell Migration Induced by Smooth Muscle Cell‐Derived Chemokine (C‐C Motif) Ligand 2 and Chemokine (C‐X‐C motif) Ligand 1 Contributes to Neointima Formation
por: Yu, Baoqi, et al.
Publicado: (2016)

Ethanol promoting the upregulation of C-X-C Motif Chemokine Ligand 1（CXCL1） and C-X-C Motif Chemokine Ligand 6（CXCL6） in models of early alcoholic liver disease
por: Jiang, Yao, et al.
Publicado: (2022)

Long-term effects of remote ischaemic preconditioning in high risk patients undergoing cardiac surgery: follow-up of a randomised clinical trial
por: Zarbock, A, et al.
Publicado: (2015)

Impacts of Chemokine (C-X-C Motif) Receptor 2 C1208T Polymorphism on Cancer Susceptibility
por: Zhou, Jing, et al.
Publicado: (2021)

Elevated signal transducers and activators of transcription 1 correlates with increased C-C motif chemokine ligand 2 and C-X-C motif chemokine 10 levels in peripheral blood of patients with systemic lupus erythematosus
por: Dominguez-Gutierrez, Paul R, et al.
Publicado: (2014)

Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma
por: Arnold, J M, et al.
Publicado: (2005)

The Effect of C-X-C Motif Chemokine 13 on Hepatocellular Carcinoma Associates with Wnt Signaling
por: Li, Chunyan, et al.
Publicado: (2015)

The Critical Role of Chemokine (C–C Motif) Receptor 2-Positive Monocytes in Autoimmune Cholangitis
por: Reuveni, Debby, et al.
Publicado: (2018)

Chemokine C-C Motif Ligand 4 Gene Polymorphisms Associated with Susceptibility to Rheumatoid Arthritis
por: Kuo, Shu-Jui, et al.
Publicado: (2018)

Role of Chemokine (C–X–C Motif) Ligand 10 (CXCL10) in Renal Diseases
por: Gao, Jie, et al.
Publicado: (2020)

Chemokine (C-C Motif) Ligand 8 and Tubulo-Interstitial Injury in Chronic Kidney Disease
por: Lee, Jangwook, et al.
Publicado: (2022)

Plasma Chemokine C-C Motif Ligand 2 as a Potential Biomarker for Prostate Cancer
por: Lund, Martin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_08ldte4ru1iakcl95ao1ptfk0a